Bone turnover markers: use in osteoporosis
Top Cited Papers
- 5 June 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Rheumatology
- Vol. 8 (7), 379-389
- https://doi.org/10.1038/nrrheum.2012.86
Abstract
Biochemical markers of bone turnover (bone turnover markers, BTMs) can be used to study changes in bone remodelling in osteoporosis. Investigators and clinicians should be aware of the appropriate sample collection and storage conditions for optimum measurements of these markers. Improvements in the variability of BTM measurements have resulted from the development of assays for automated analysers, and from international consensus regarding their use. Appropriate reference intervals should be used for the optimum interpretation of results. BTMs can provide information that is useful for the management of patients with osteoporosis, for both the initial clinical assessment and for guiding and monitoring of treatment. BTMs are clinically useful to determine possible causes of secondary osteoporosis by identifying patients with high bone turnover and rapid bone loss. In the follow-up of treatment response, BTM levels respond rapidly to both anabolic and antiresorptive treatments. BTM changes can also be used for understanding the mechanism of action of drugs in development and identifying the correct dose; they are also potentially useful as surrogate biomarkers for fracture.Keywords
This publication has 142 references indexed in Scilit:
- Effect of Stopping Risedronate after Long-Term Treatment on Bone TurnoverJournal of Clinical Endocrinology & Metabolism, 2011
- Determinants of serum sclerostin in healthy pre- and postmenopausal womenJournal of Bone and Mineral Research, 2011
- Relation of age, gender, and bone mass to circulating sclerostin levels in women and menJournal of Bone and Mineral Research, 2010
- Serum Sclerostin Levels Negatively Correlate with Parathyroid Hormone Levels and Free Estrogen Index in Postmenopausal WomenJournal of Clinical Endocrinology & Metabolism, 2010
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisThe New England Journal of Medicine, 2009
- Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone ClubInternational Journal of Clinical Practice, 2008
- Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trialBone, 2008
- Establishing a reference range for bone turnover markers in young, healthy womenBone, 2008
- Effect of Fracture on Bone Turnover Markers: A Longitudinal Study Comparing Marker Levels Before and After Injury in 113 Elderly WomenJournal of Bone and Mineral Research, 2007
- Biochemical Markers of Bone Metabolism and Prediction of Fracture in Elderly WomenJournal of Bone and Mineral Research, 2004